• Brussels publishes the contract with AstraZeneca.

    Here is the text

  • The EU Commission publishes the contract with AstraZeneca.

    Von der Leyen: "Clear and binding"

  • Astrazeneca open to increase plants in the EU.

    London: "Vaccines destined for us remain in GB"

  • Vaccini, is a clash between Europe and Astrazeneca.

    EU: respect the agreements.

    The company: no obligation

  • Astrazeneca.

    Ema: evaluations on effectiveness over 65. The company: falsehood, we respect the contract

Share

January 29, 2021 The European Medicines Agency approved the AstraZeneca vaccine for over 18s.

Now the Commission should follow up with the marketing authorization.



"The EMA Committee for Medicinal Products for Human Use (CHMP) has thoroughly evaluated the data on the quality, safety and efficacy of the vaccine and recommended by consensus the granting of a formal conditional marketing authorization by the European Commission. This will ensure EU citizens that the vaccine meets EU standards and puts in place safeguards, controls and obligations to support EU-wide vaccination campaigns ", reads a note from 'Ema. 



📢 EMA has just recommended granting a conditional marketing authorization for the # COVID19vaccine AstraZeneca to prevent # COVID19 in people from 18 years of age.

👉Read our press release: https://t.co/YDbOvZEMUN pic.twitter.com/Sbj6TdlGTW

- EU Medicines Agency (@EMA_News) January 29, 2021


Speranza: "Encouraging news"


The Minister of Health, Roberto Speranza, commented on Facebook: "Encouraging news. The battle against the virus is still complex, but having another effective and safe vaccine available gives us more strength in the vaccination campaign ".



AstraZeneca: "Effective, well tolerated, easy to administer"


"Today's recommendation highlights the value of AstraZeneca's Covid-19 vaccine which is not only effective and well tolerated, but also easy to administer and importantly, fully protects against serious disease and hospitalizations. We are deeply grateful to the University of Oxford, clinical trial participants and colleagues at AstraZeneca for their unwavering commitment to providing this life-saving vaccine to millions of Europeans. "

Thus Pascal Soriot, CEO of AstraZeneca, comments on the approval of the anti-Covid vaccine by the EMA.